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Abstract
Leptin gains access to the central nervous system where it influences activity of neuronal networks
involved in ingestive behavior, neuroendocrine activity, and metabolism. In particular, the brain
melanocortin (MC) system is important in leptin signaling and maintenance of energy balance.
Although leptin or MC receptor insensitivity has been proposed to be associated with obesity, the
present study compared central leptin and MC receptor stimulation on some of the above-mentioned
parameters and investigated whether these treatments predict proneness to diet-induced obesity
(DIO) in out-bred Wistar rats. Third-cerebroventricular administration of equi-anorexigenic doses
of leptin and of the MC agonist melanotan-II caused comparable increases in plasma ACTH and
corticosterone levels and c-Fos-labeling in approximately 70% of paraventricular hypothalamic
(PVN) neuronal cell bodies containing CRH. This reinforces involvement of paraventricular CRH
neurons in the short-term neuroendocrine and ingestive effects of leptin and melanocortins. In the
DIO prediction study, anorexigenic efficacy of melanotan-II was not correlated with any parameter
linked to DIO but was highly correlated with MC in situ binding (with labeled [Nle4,D-Phe7]α-MSH)
as well as CRH immunoreactivity in the PVN of DIO rats. This suggests intricate relationships among
MC signaling, the CRH system, and ingestive behavior unrelated to DIO. In the same animals, leptin’s
anorexigenic efficacy was not correlated with PVN MC in situ binding or CRH immunoreactivity
but correlated inversely to post-DIO plasma leptin, liver weight, and abdominal adiposity, the latter
being correlated to insulin resistance. Thus, differences in leptin but not MC signaling might underlie
DIO, visceral obesity, and insulin resistance.
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AgRP, Agouti-related protein; Arc, arcuate hypothalamus; AUC, area under the curve; cFLI, c-Fos-
like immunoreactivity; CNS, central nervous system; DIO, diet-induced obesity; HED, high-energy
diet; HPA, hypothalamo-pituitary-adrenal; i3cv, third cerebral ventricle; IVGTT, iv glucose
tolerance test; Mag, magnocellular; MC, melanocortin; MTII, melanotan-II; Par, parvocellular;
POMC, proopiomelanocortin; PVN, paraventricular hypothalamus; VMH, ventromedial
hypothalamus
LEPTIN, THE 167-AMINO-ACID product of the OB gene, is synthesized and secreted mainly by adipose
tissue roughly in proportion to the size of adipose tissue mass in the body (1,2). There is
compelling evidence that this hormone is involved in the long-term regulation of energy
balance (3). Its actions in the central nervous system (CNS) are thought to close a feedback
loop from adipose tissue to neuronal circuitry that regulates food intake, neuroendocrine
outflow, and metabolism in a coordinated fashion (3). This idea is based on findings that
infusion of a relatively low dose of leptin into the third cerebral ventricle (i3cv) of rats causes
profound reductions in food intake (4,5) and body fat mass even independent of food intake
effects (6). The fact that rodents and humans with genetic deficiencies in the leptin system
become morbidly obese supports the importance of leptin in regulation of energy balance (7,
8).
A key neuronal circuit involved in the signaling of leptin originates from neuronal cell bodies
in the arcuate hypothalamus (Arc) that synthesize proopiomelanocortin (POMC). POMC is
cleaved into several splice products among which α-MSH may be most relevant for regulation
of energy balance. α-MSH acts agonistically on specific brain melanocortin MC3 and MC4
receptors (9). Other neurons in the Arc produce agouti-related protein (AgRP), which acts
antagonistically on these receptors (9). Because leptin up-regulates expression of POMC
mRNA and down-regulates AgRP mRNA in Arc neuronal cell bodies (6,10), these opposing
actions of α-MSH and AgRP on MC receptors probably exert a dual input on brain MC
receptors. The idea that MC receptors act downstream from leptin signaling is consistent with
the finding that co-infusion of the MC3–4 receptor antagonist with leptin prevents leptin’s
anorexigenic efficacy and neuronal activation of the paraventricular hypothalamic nucleus
(PVN) (4). The latter is known to be an important structure in regulation of food intake,
neuroendocrine outflow, and metabolism and includes, among others, neuronal cell bodies that
synthesize CRH (11).
The MC system received considerable attention over the last several years because mutations
in the DNA encoding MC receptors, POMC, or POMC splicing enzyme have been associated
with moderate to severe forms of human (12) and animal (9) obesity. Important evidence
demonstrating that reduced MC receptor stimulation in the CNS leads to obesity is consistent
with our observation that central, but not peripheral, administration of the MC receptor
antagonist SHU9119 in rats causes dramatic increases in food intake and body weight, and it
leads to several metabolic derangements associated with obesity (13). Although spontaneous
genetic MC deficiencies render humans relatively frequently hyperphagic and obese (for
example, relative to spontaneous deficiencies in leptin synthesis or reception), still the majority
of screened obese subjects has no apparent mutation in the MC system. It might be
hypothesized, however, that signaling of endogenous MC receptor ligands varies dramatically
among subjects (e.g. as a result of differences in receptor number or downstream signaling
cascades), and those with the lowest sensitivity could be most obesity prone, particularly when
challenged with a high-energy diet (HED).
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To further explore whether differences in MC receptor signaling might be relevant for the
etiology of diet-induced obesity (DIO), we performed two experiments in rats. In the first
experiment, we characterized short-term anorexigenic efficacies and activation patterns of
PVN neurons (by using c-Fos and CRH double staining) and neuroendocrine outflow after
i3cv administration of different doses of the synthetic MC receptor agonist melanotan-II (MTII)
(Ac-Nle4-c [Asp5,D-Phe7,Lys10]α-MSH-(4–10-NH2). In the second experiment, it was
investigated whether reduced sensitivity to one of the doses of MTII (with relative suppression
of food intake as readout parameter) correlates to the development of DIO and associated
metabolic derangements in rats challenged with a HED. MC receptor in situ binding
[with 125I-labeled [Nle4,D-Phe7]α-MSH (NDP-MSH)] was performed after HED exposure to
reveal whether reduced MC receptor binding in certain brain regions might be associated with
DIO. These studies are important considering the fact that MC agonists are candidate drugs in
the prevention or treatment of obesity. In both studies, the effects of MTII were compared with
those of leptin, anticipating that we could reproduce the findings of Levin et al. (14) who
previously reported that leptin insensitivity is a marker for DIO.
Materials and Methods
Animal preparation
A total of 47 male Wistar rats weighing between 360 and 390 g were individually housed in
Plexiglas cages (25 × 25 × 30 cm) in a colony room with a 12-h light, 12-h dark cycle and
normal ambient temperature (20 × 2 C). Pelleted chow and water were continuously available
(except where noted). All animals were given a 21-gauge stainless steel cannula (Plastics One,
Roanoke, VA) aimed at the third cerebral ventricle (at 1.5 mm posterior to Bregma and 7.5
mm ventral to dura) according to methods previously described (5). One week after surgery,
brain cannula placements were confirmed by i3cv administration of 10 ng an-giotensin II in 1
μl sterile saline. This and all other i3cv administrations were performed with an injector that
extended 1 mm beyond the tip of the brain cannula. Animals that did not drink 5 ml of water
within 60 min after angiotensin II administration were excluded from the experiment (n = 1).
Continuing rats were allowed to recover for at least 2 wk, during which they all returned to
above presurgical body weights. In addition to the brain cannula, 36 rats also received a silicon
catheter (od, 0.95 mm; id, 0.50 mm) inserted into the right jugular vein according to techniques
described elsewhere (15). This catheter allowed frequent repeated blood sampling and/or
infusion of fluids in undisturbed freely moving rats. Patency of the blood sampling catheters
was checked weekly. Before experiments, animals were accustomed on 3 different days to
brain injection and/or blood sampling procedures. All these and other procedures mentioned
below are in accordance with the guidelines of the Animal Ethics Committee of the University
of Groningen.
Experimental design
Assessment of MTII and leptin effects on food consumption—On 2 experimental
days, food was removed 2 h before the dark phase and rats (n = 10, with i3cv cannulas only)
were weighed. On the first experimental day, rats were divided into two groups matched for
body weight (n = 5). One group was i3cv infused with sterile saline (3.0 μl), and the other was
i3cv infused with leptin [3.0 μg human leptin (PreproTech, London, UK) in 3.0 μl saline]. After
1 wk, five rats (two and three randomly assigned rats from, respectively, the saline-infused and
leptin-infused group) were i3cv infused with 0.05 μg MTII (Sigma Chemical Co., St. Louis,
MO), whereas the remaining five animals were i3cv infused with 0.5 μg MTII. This order of
administration was chosen because we have previously shown that i3cv MTII treatment may
have some aversive side effects (16). For infusion, an animal was taken from its cage between
2 and 1 h before lights off. While sitting unrestrained on the experimenter’s lap, the obturator
was removed and a 26-gauge infusion cannula connected to PE-20 infusion tubing was inserted
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into the guide cannula. This infusion cannula extended 1.0 mm beyond the tip of the guide
cannula. Solutions were manually infused with a Hamilton syringe over 60 sec. Immediately
after infusion, the injector was replaced by the obturator, and animals were returned to their
home cage. Food was weighed and returned to the cage at lights off, and food intake was
assessed after 3 h in the dark phase and overnight.
Assessment of MTII and leptin effects on neuroendocrine and PVN neuronal
activity—At 4.5 h before lights off, other rats (n = 22) were briefly taken from their cages
and connected with their jugular vein catheter to blood sampling tubing (PE 50, length 50 cm)
and i3cv infusion tubing such that these extended out of their cages. Upon return, their food
was removed, and animals were left alone for at least 30 min. During a 2-h window ending 2
h before lights off, a blood sample (1 ml) was taken and immediately thereafter, groups matched
for body weight were i3cv infused with one of four solutions (leptin, 3.0 μg, n = 5; MTII, 0.05
μg, n = 7; MTII, 0.5 μg, n = 6; or vehicle, n = 6). Second and third blood samples (each 1 ml)
were taken at 45 and 90 min after i3cv infusion. Blood samples were collected for measurement
of glucose, ACTH, corticosterone, catecholamines, glucagon, leptin, and insulin in vials kept
on melting ice, which contained aprotinin and EDTA, homogenized, and immediately
centrifuged (15 min at 4300 rpm at 4 C), and stored at −80 C until determination. After each
blood sample was taken, a transfusion of a similar volume of heparinized donor blood (taken
from undisturbed donor rats) was iv infused into the animals to avoid reduction of blood
volume. After the last blood sample, animals were anesthetized with sodium pentobarbital (6%,
0.5 ml, iv) and transcardially perfused with isotonic PBS followed by 4% paraformaldehyde
in 0.1 M phosphate buffer. Brains were removed and postfixed for approximately 24 h and then
processed for c-Fos-like immunoreactivity (cFLI) and CRH-like immunoreactivity.
Assessment of sensitivity to MTII and leptin and their predictiveness for DIO
and related derangements—After rats (n = 12) with i3cv cannulas and jugular vein
catheters had surpassed their preoperative body weights minimally at 1 wk, the anorexigenic
efficacies of MTII (0.05 μg) and leptin (3.0 μg) relative to saline were investigated. These
doses of MTII and leptin were chosen based on their similar anorexigenic efficacies as shown
in the previous experiments. Food was removed 2 h before the dark phase, and between 2 and
1 h before lights off, rats were weighed and i3cv infused with MTII or leptin in randomized
order with 1 wk between successive experiments. Before and in between drug treatments, rats
were i3cv infused with saline (3 μl). After each i3cv infusion, food was weighed and returned
to the cage at lights off, and food intake was assessed overnight. The efficacy of drugs to reduce
food intake in each individual animal was expressed as follows: [(food intake after drug −
average food intake after saline)/average food intake after saline] × 100%. After the sensitivity
tests, rats were given, in addition to their normal chow, free access to a palatable liquid HED
over a period of 16 wk. This diet consisted of a 10% sucrose solution in which corn oil was
emulsified. This diet was based on the work of Lucas and Sclafani (17) and Smith et al. (18)
and causes DIO in rats (19). The concentration of corn oil was doubled every 2 wk starting
with 4% and finally ending up at 32% corn oil over the last weeks. The diet was freshly made
each day, and specifics for preparation can be found elsewhere (19). Food intake (chow and
HED) and body weight of rats were assessed on the final day of each dietary step.
During the final week of HED exposure, all rats were challenged with an iv glucose tolerance
test (IVGTT). Specifically, food hoppers and the HED were removed at lights on, and 4 h later
rats were connected to the blood sampling tubing and again left alone for 1 h. After taking a
baseline blood sample (each 150 μl), 1.5 ml of a 10% glucose solution was iv injected over a
period of 15 sec (t = 0) and blood samples were taken at t = 1, 3, 5, 7, 10, and 15 min. Thereafter,
rats were disconnected from their blood sampling tubing and access to food was allowed again.
The samples were immediately transferred to heparinized tubes (kept on melting ice) from
which 50 μl blood was directly taken for determination of blood glucose. After centrifugation
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(15 min at 4300 rpm at 4 C), the remaining plasma was stored at −20 C until analysis for plasma
insulin concentration. Three days after the IVGTT, animals were anesthetized with CO2
between 2 and 4 h after lights on and decapitated within 30 sec, and their brains were removed
from the crania and deeply frozen on dry ice and stored at −80 C. Trunk blood was collected
for measurement of ACTH, corticosterone, leptin, insulin, and glucose in vials (kept on melting
ice) containing aprotinin and EDTA, centrifuged (15 min at 4300 rpm at 4 C), and stored at
−80 C until determination. Weights of liver, gastrointestinal tract (full and empty), and fat pads
(epididymal, mesenteric, and retroperitoneal) were assessed.
Chemical determinations and immunohistochemistry
Determination of plasma concentrations of insulin, ACTH, glucagon, and leptin were
performed using sensitive RIAs (Linco Research, St. Charles, MO). Plasma concentrations of
glucose, cholesterol, free fatty acids, and liver triglyceride content were assessed enzymatically
(Boehringer kits; Boehringer, Mannheim, Germany). Plasma corticosterone (20) and
catecholamines (21) were analyzed by HPLC. Determination of liver glycogen content was
assessed as previously described (13).
For c-Fos immunohistochemistry and CRH double labeling, 40-μm coronal slices were cut on
a vibrotome from the forebrain and included sections through the PVN. The sections were
collected as alternate sets, with one set processed for immunoreactivity and the other stained
with cresyl-violet for anatomical definition. Tissues were rinsed in PBS, incubated for 20 min
in 0.3% H2O2 in absolute methanol to quench endogenous peroxidase, rinsed, and incubated
1 h in 1% gelatin, 5% normal goat serum in PBS. Slices were then transferred without rinsing
to the primary antibody solution consisting of 0.005 g/ml polyclonal rabbit antiserum (Santa
Cruz Biotechnology, Santa Cruz, CA) (1:20,000), which recognizes residues 3–16 of the c-
Fos protein. After approximately 48 h incubation on ice (4 C), slices were rinsed and processed
using the ABC method (Vector Laboratories, Burlingame, CA). Slices were transferred to
biotinylated goat antirabbit antibody for 1 h, rinsed, and developed with diaminobenzidine
substrate intensified with nickel sulfate (6 min), which produced dark cFLI nuclei. After an
overnight rinse in PBS, sections were run through a second assay using the same procedure as
above, except that the primary antibody was rabbit anti-CRH (1:10,000) and sections were
developed in diaminobenzidine substrate without the nickel sulfate (which produced light-
brown cell bodies). Thus, double-labeled cells were seen as dark nuclei surrounded by light-
brown cell bodies. Finally, slices were rinsed (10× PBS), mounted on slides, and coverslipped
with Permount. Camera lucida drawings from c-Fos immunoreactive sections were prepared
and scored by a blind rater who recorded the number and location of c-Fos-positive nuclei in
one slice of each rat revealing the PVN most optimally at 1.7 mm caudal from Bregma
according to the brain atlas of Paxinos and Watson (22). In these slices, counts were also made
of CRH-positive cells and of cells that coexpressed the c-Fos and the CRH proteins.
Brains from rats that were rendered diet-induced obese were cut as 25-μm coronal slices (using
a cryostat microtome), which included the area covering the PVN to the ventromedial
hypothalamus (VMH) (from −1.5 to −3.5 relative to Bregma), and immediately taken up on
gelatin-coated slides. Two sets were postfixed with 4% paraformaldehyde in 0.1 M phosphate
buffer on glass and dried (48 h at 30 C) for cresyl violet staining and CRH
immunohistochemistry. A third set was dehydrated with silica gel used for in situ binding
with 125I-labeled NDP-MSH. CRH immunohistochemistry was performed according to the
same techniques as above. CRH-positive neurons were found after peroxide-antiperoxide
labeling of the complex (peroxidase-antiperoxidase immunoprocessing). The assay for [125I]
NDP-MSH in situ binding was performed according to the methods described by Vrinten and
colleagues (23). In short, sections were prewashed, incubated with [125I]NDP-MSH (106 cpm/
ml) in binding buffer for 1 h, washed six times to stop binding reactions, and rapidly air dried.
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Also sections were incubated with [125I]NDP-MSH in the presence of noniodinated NDP-MSH
to determine the specificity of tracer. All binding assays were on the same day in one
experimental session. Autoradiography was performed by exposing an x-ray film directly to
slices for 2 wk. Autoradiograms harboring the PVN and the VMH were digitized and
quantitatively analyzed using a Leica Quantimet Image Analysis System (Quantimet
Q-600HR; Leica, Wetzlar, Germany). The PVN and VMH were found and outlined using
adjacent cresyl-violet-stained sections for the VMH and an adjacent CRH-stained section for
the PVN. Absorbance levels within the outlined bilateral PVN and VMH were determined,
and specific binding was calculated by subtraction of the mean background value, determined
within the ventral-lateral thalamus of the same sections. The absorbance values were compared
with those found in a linear calibration curve, and levels fitted well within the linear part of
this curve. The level of CRH immunohistochemistry was assessed in four to six PVNs
bilaterally of each animal. This was done by assessing the absorbance over the entire PVN
region using the Leica Quantimet Image Analysis System. Background absorbance was also
determined in the area in close vicinity of the PVN and was subtracted from the value obtained
from the PVN region.
Statistical analyses
ANOVA was used to investigate effects of i3cv saline vs. MTII (two doses) vs. leptin on
overnight food intake, neuronal activation, and changes in blood parameters. Spearman’s ρ
nonparametric analysis was used to assess correlations of the anorexigenic efficacy of i3vt
administered MTII and leptin with hormonal and metabolic parameters linked to DIO, as well
as with the intensity of 125I-labeled NDP-MSH in situ binding and paraventricular CRH
immunostaining.
Results
Effects of MTII and leptin food consumption
The effects of i3cv saline, leptin, and the two dose of MTII on 3-h and overnight food intake
are presented in Table 1. ANOVA revealed a significant drug effect on both 3-h (F3,22 = 10.77;
P < 0.0001) as well as overnight (F3,22 = 20.47; P < 0.0001) food intake. Post hoc tests revealed
that i3cv leptin and the two doses of MTII produced significant reductions in food intake
compared with the saline group. Whereas food intake was comparably reduced with leptin and
the 0.05-μg dose of MTII at 3 h (respectively, −57 and −65%) and overnight (respectively, −35
and −45%), the 0.5-μg dose of MTII produced a significantly more pronounced reduction in
overnight food intake (respectively, −89 and −79%) relative to 0.05 μg MTII and leptin
treatment.
Assessment of MTII and leptin effects on neuroendocrine and PVN neuronal activity
The effects of i3cv saline, leptin, and the two doses of MTII on plasma levels of ACTH,
corticosterone, and leptin are presented in Fig. 1. Two animals could not be used for blood
sampling (one in the vehicle and one in the 0.05-μg MTII group) because of occlusion of blood
sampling catheters. Repeated-measures ANOVA revealed significant effects on plasma
corticosterone (time × drug: F6,38 = 5.88; P < 0.0001), ACTH (time × drug: F6,38 = 7.08; P <
0.0001), and leptin (time × drug: F6,38 = 12.39; P < 0.001). Plasma levels of corticosterone
after i3cv leptin and MTII were higher relative to vehicle treatment. The 0.5-μg dose of MTII
caused significantly higher levels of plasma corticosterone relative to the 0.05-μg dose of MTII.
Significantly higher levels of ACTH were found at all time points after MTII and leptin relative
to the vehicle. The 0.5-μg dose of MTII caused higher levels of plasma ACTH relative to the
0.05-μg dose and leptin at time point t = 45 min. Only higher plasma levels of leptin were found
after i3cv leptin administration.
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The effects of i3cv saline, leptin, and the two doses of MTII on plasma levels of glucagon,
epinephrine, and norepinephrine are presented in Fig. 2. Repeated-measures ANOVA revealed
significant effects on plasma epinephrine levels (time × drug: F6,38 = 4.62; P = 0.001). Post
hoc analysis revealed significantly higher levels of plasma epinephrine after i3cv MTII but not
after i3cv leptin. Although an ANOVA including all groups did not attain a significant effect
on plasma glucagon levels, there appeared to be an elevation of plasma glucagon with i3cv
MTII (0.5 μg) (F2,20 = 3.65; P = 0.045). ANOVA did not reveal any effects on norepinephrine
or on plasma insulin and glucose (the latter are not shown).
Areas under the curve (AUC) of the significantly affected plasma parameters were calculated
and presented in Table 2. ANOVA revealed significant effects of treatment on the AUC of
plasma ACTH (F3,21 = 6.06; P = 0.005), corticosterone (F3,21 = 14.22, p = <0.0001), leptin
(F3,21 = 21.35; P < 0.0001), and epinephrine (F3,21 = 3.74; P < 0.03). Post hoc analysis revealed
that both doses of MTII and leptin caused increases in the AUC of the plasma ACTH and
corticosterone responses, whereas only leptin caused an increase in the AUC of leptin. Only
the highest dose of MTII caused an increase in the AUC of the plasma epinephrine response.
I3cv saline treatment did not result in an increased AUC of any assessed parameter.
Gross inspection of brain slices clearly revealed CRH-positive neurons (stained as light brown)
in the PVN (see Fig. 3A), mostly in the parvocellular (PVN-Par) division (Fig. 3B), but only
to a small extent in the magnocellular (PVN-Mag) division. This is in agreement with the data
of Sawchenko et al. (24). cFLI could be observed as black staining of nuclei within CRH-
positive as well as in CRH-negative cells. Data from cFLI in PVN-Par and PVN-Mag are
presented in Table 3. ANOVA revealed significant drug effects on cFLI in PVN-Par (F3,18 =
7.56; P = 0.0017) as well as PVN-Mag (F3,18 = 7.35; P = 0.002). Post hoc tests comparing the
control group with drug-treated groups revealed that leptin (P = 0.014) (Fig. 3, C and D) and
the two doses of MTII [0.05 μg, P = 0001 (Fig. 3, E and F); 0.5 μg, P = 0.0025 (Fig. 3, G and
H)] produced increased cFLI in the PVN-Par. With respect to the PVN-Mag, only the two
doses of MTII (0.05 μg, P = 0.0035; 0.5 μg, P = 0.0078) produced reliably increased cFLI
relative to that observed after saline treatment, whereas leptin effects on cFLI were not different
from saline treatment. In addition, both doses of MTII (0.05 μg, P = 0.012; 0.5 μg, P = 0.019)
also produced increased cFLI relative to leptin treatment. The percentages of cFLI-positive
neurons that contained CRH were significantly elevated in all treatment groups relative to
saline (F3,18 = 69.06; P < 0.00001). Levels of double labeling were not different among groups
despite differences in c-Fos labeling.
Assessment of sensitivity to MTII and leptin and their relation to DIO and related
derangements
Before, between, and after sensitivity tests with MTII and leptin, 12 rats were i3cv treated at
three different times with saline. On consecutive occasions, the mean overnight food intake
was 17.2 ± 0.6, 16.9 ± 0.9, and 16.9 ± 1.7 g, respectively, with the individual intakes replicated
within relatively narrow margins. Because these outcomes were similar, the effect of saline
treatment on food intake was expressed as average of the three outcomes for each individual
animal. Overnight food intake of rats after i3cv MTII (0.05 μg) and leptin (3.0 μg) was 7.5 ±
1.7 and 9.7 ± 0.9 g, respectively, and these effects were not different from each other. Although
there were large individual differences in the anorexigenic efficacy of leptin (between −84
and-12% relative to saline) and MTII (between −93 and −3%), these sensitivities were not
correlated (see Table 4). No correlations were found of anorexigenic efficacies of leptin and
MTII with plasma leptin levels before HED exposure.
HED exposure caused an increase in energy intake with each dietary step (relative to a group
of nontreated controls that are not shown in the current study) to finally a level at the 16th week
of exposure, which was on average 128% higher than intake at baseline, and this was solely a
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result of the increased intake of the sucrose/corn oil mixture. There was, in fact, a slight decrease
in the intake of chow (12% suppression relative to basal intake). This is consistent with one of
our previous studies using the same paradigm, which finally led to an 82% increase in body
weight relative to a group of rats that were left on chow (19).
During the last week of HED exposure, rats were subjected to IVGTTs. Upon iv injection of
glucose, blood glucose levels rose from 6.84 ± 0.24 mmol/liter to a maximum level of 14.38
± 0.49 mmol/liter at t = 1.5 min and then returned to basal levels at t = 15 min. Whereas the
blood glucose responses to the IVGTT did not vary to a large extent between animals, the
plasma insulin responses to IVGTTs, however, varied dramatically among rats. Expressed as
AUC relative to baseline levels, insulin responses varied between 82.7 and 348.4 ng/ml·15
min. Postmortem assessment of parameters related to nutritional status revealed that abdominal
fat mass varied between 36.0 and 71.8 g, liver weights between 17.8 and 22.5 g, and plasma
levels of leptin between 5.3 and 33.1 ng/ml. Within the hypothalamus, 125I-labeled NDP-MSH
binding revealed strong signaling in the PVN and ventro-medial hypothalamus (VMH), and
CRH immunohistochemistry revealed strong labeling only of PVN neurons.
Correlation analysis of post-DIO parameters revealed significant interactions between
abdominal fat mass and leptin concentration and the AUC of the plasma insulin response to
the IVGTT. The anorexigenic efficacy of leptin, but not of MTII, before the DIO appeared to
be highly inversely correlated to the post-DIO plasma leptin concentration, post-DIO
abdominal fat mass, post-DIO liver weight (Fig. 4), and hepatic glycogen content (P = 0.005;
r = 0.74) but not to hepatic triglyceride storage (P = 0.08; r = 0.21). The anorexigenic efficacy
of MTII, but not of leptin, was correlated to post-DIO CRH labeling in the PVN and to the
post-DIO 125I-labeled NDP-MSH binding specifically in the PVN but not to the VMH (Fig.
5). All correlation coefficients and levels of significance not indicated here are presented in
Table 4.
Discussion
A number of reports suggest that the effects of leptin are mediated, in part, via activation of
PVN neurons that synthesize and secrete CRH (25–29). One hypothesis proposes that reduced
sensitivity of brain MC receptors might underlie the development of DIO (30). The present
study was designed to explore the relevance of interactions between MC receptor sensitivity
and PVN CRH neurons in the etiology of DIO and associated metabolic derangements. The
latter is an extremely important issue in public health, because the prevalence of obesity and
the metabolic syndrome are increasing to epidemic proportions (31,32), and treatment is not
yet available.
In the present study, equi-anorexigenic doses of leptin (3.0 μg) and MTII (0.05 μg) caused
identical increases in cFLI of PVN-Par neurons. Double-labeling immunohistochemistry
revealed that approximately 70% of these cFLI-positive PVN neuronal cell bodies colabeled
CRH with either treatment. A higher dose of MTII (0.5 μg) with a notably stronger anorexigenic
efficacy caused stronger cFLI in the PVN. The ratio of CRH-positive and cFLI-positive
neuronal cell bodies remained unaltered with the higher MTII dose, which indicates that in
total more CRH neurons were activated relative to that caused by the lower dose of MTII or
leptin. The presumably increased CRH output caused by the high MTII dose may also be the
result of a stronger activation of CRH neurons, which would be stimulated with the lower dose
of MTII as well. Unfortunately, c-Fos immunohistochemistry is not a suitable method to clarify
this issue. Nevertheless, together with observations by others that the anorexigenic effects of
leptin (26,27) as well as MTII (28) can be prevented by co-infusion of the CRH receptor
antagonist, α-helical-CRH (9–41), these data lend further support to the idea that CRH-
producing PVN neurons, at least in the short term, are key in leptin receptor-mediated as well
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as MC receptor-mediated reductions in food intake (29). The effects of MTII on CRH neurons
is probably direct, because MC4 receptors have been demonstrated to exist on PVN neuronal
cell bodies that express CRH (28). Thus, in the case of stimulation of CRH neurons by leptin,
this probably requires activation of POMC-containing neuronal cell bodies in the Arc (10,
33), which then release the endogenous MC receptor ligand α-MSH from their nerve terminals
adjacent to MC4 receptors on PVN neuronal cell bodies (28). Indeed, α-MSH has previously
been demonstrated to increase phospho-cAMP response element binding protein in
paraventricular CRH neurons (29). The idea that leptin-mediated activation of PVN CRH
neurons depends on the integrity of the MC system is in agreement with the observations of
Seeley et al. (4) that i3cv co-infusion of the MC3/4 receptor antagonist SHU9119 blocked not
only leptin’s anorexigenic efficacy but also its stimulatory effects on cFLI in the PVN.
Whereas the projections of PVN CRH neurons as well as their subclasses of CRH receptors
that contribute to the regulation of food intake are currently being unraveled (e.g. Refs. 34 and
35), the classical contribution of PVN CRH neurons to the activity of the hypothalamo-
pituitary-adrenal (HPA) axis has been already known for over two decades (36). The similar
acute activation patterns of PVN CRH neurons by equi-anorexigenic doses of leptin and MTII
were associated with similar increments in the plasma levels of ACTH and corticosterone.
Although leptin presumably influences neuropeptide/neurotransmitter systems that regulate
food intake and neuroendocrine activity independent from the MC-CRH axis (e.g. Refs. 37–
39), one implication of these data may be that these parallel systems are less important within
a time frame of less than a few hours. Indeed, the magnitudes by which food intake, HPA axis
activity, and PVN CRH neuronal activity were affected by i3cv administered leptin and MTII
were markedly similar. In the long term, however, leptin and MTII might greatly differentiate
with respect to their anorexigenic efficacies, CRH and HPA axis activation, and other endocrine
and metabolic parameters. In fact, leptin has been shown in usually more chronic infusion
paradigms (i.e. with osmotic minipump infusion over several days to weeks) to decrease CRH
mRNA expression and/or HPA axis activity (e.g. Refs. 40–42), as opposed to the effects of
MC receptor agonists (de Vries, K., and G. van Dijk, unpublished observations). It might be
possible that the short-term effects of leptin and MTII to stimulate paraventricular CRH
neurons may not engage a physiological mechanism to cause a reduction in food intake but
that it signals an emergency situation. Indeed, a variety of psychological and physical stressors
increase the expression of CRH in the PVN, and leptin and MTII may simply tie into this
mechanism. However, it needs to be mentioned here that involuntary overfeeding in rats causes
increased activation of the MC-CRH axis (43,44). Although the exact mechanism underlying
this effect remains to be investigated, it may be argued that the dramatic increase in leptin under
conditions of involuntary overfeeding signals an increase in the nutritional status that animals
might have difficulties in dealing with in a homeostatic sense (45). Thus, along these lines, it
might very well be possible that a sudden increase in the ambient leptin level caused by
exogenous application may signal an abrupt increase in the nutritional status and would thus
be relayed as an emergency situation. A potential effect of leptin to induce discomfort, nausea,
or pain per se is less likely because a similar dose of leptin used in one of our previous studies
was not capable of inducing a conditioned taste aversion (46).
Besides similarities in activation pattern of PVN neurons and neuroendocrine and behavioral
correlates after i3cv lep-tin and MTII, we observed that i3cv leptin, but not i3cv MTII (even
dosed at the 0.5-μg concentration), led to an elevation of peripheral plasma leptin levels.
Although we do not know the mechanism underlying this phenomenon (see also Ref. 47), we
have neither observed elevated plasma leptin levels after i3cv leptin administration in Zucker
rats (van Dijk, G., unpublished observations) nor found traces of the i3cv infused human leptin
in plasma in previous studies (6,47). For these reasons, we believe that this effect is caused via
a receptor-mediated action in the CNS but does not require increased activation of brain MC
receptors. Another striking difference between the effects of the two treatments was that i3cv
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MTII but not i3cv leptin administration caused a rise in the circulating level of epinephrine
and glucagon, and this was particularly evident when MTII was dosed at a higher concentration.
It might be speculated that these effects are mediated via a subset of MTII-sensitive PVN
neurons, which project to adrenal medullary sympathetic preganglionic neurons (48) and
potentially to the preganglionics of the pancreas as well.
In a distinct group of rats, the anorexigenic efficacies of i3cv MTII and leptin were assessed
relative to saline treatment, and thereafter these rats were subjected to a palatable HED known
to induce DIO (19). The i3cv doses of leptin and MTII caused overall reductions in food intake
that were comparable to those in the dose-response study mentioned above. There were,
however, large individual differences in the responses between rats; i.e. some rats responded
to i3cv leptin administration with an almost 100% reduction relative to control treatment,
whereas others were markedly insensitive. This degree of variability was also observed after
i3cv MTII treatment, but the individual anorexigenic efficacy of MTII in rats was not related
to that of leptin. After feeding the HED for several months, a number of parameters related to
obesity were highly correlated to the initial anorexigenic efficacy of leptin. Specifically, rats
that were relatively insensitive to leptin’s anorexigenic actions displayed the largest HED-
induced weight gain in the form of abdominal fat deposition and liver weight and had the
highest plasma levels of leptin. Thus, although DIO (49) and hyperleptinemia (50) have been
shown to induce leptin resistance, these data suggest that leptin insensitivity could in fact
underlie hyperleptinemia and DIO, and this confirms and extends previous findings of Levin
et al. (14).
The abdominal fat mass of rats after HED exposure was significantly correlated to the AUC
of the insulin response during the IVGTT. An increase in the insulin response to an IVGTT
may be considered as an indicator of reduced insulin sensitivity (51), and this finding is in
agreement with many observations that increased abdominal obesity is associated with insulin
resistance (52). Because abdominal fat deposition was inversely correlated to leptin’s
anorexigenic efficacy and because increased leptin signaling (53,54) as well as MC signaling
(55) in the CNS are known to increase whole-body insulin sensitivity, one might have expected
a relationship between leptin and/or MTII’s anorexigenic efficacy and insulin sensitivity.
However, neither the anorexigenic efficacy of leptin nor that of MTII was directly correlated
to the AUC of insulin during the IVGTT. Thus, although the IVGTTs were performed in rats
food deprived no longer than 4 h, the data in the present study suggest that the primary effect
of reduced central leptin sensitivity is diet-induced (visceral) obesity, and peripheral insulin
resistance is presumably a secondary feature of this. In this respect, the strong inverse
correlation between leptin’s anorexigenic efficacy and the post-HED liver weight is of interest,
given the previous finding by Cohen et al. (56) that mice with targeted deletion of central leptin
receptors have enlarged livers and are obese, and central leptin deficiency has been proposed
to increase hepatic lipid storage via increased activity of the hepatic enzyme, stearoyl-CoA
dehydrogenase (57). In the present study, however, we observed only a tendency of an inverse
correlation between the post-HED hepatic triglyceride content with leptin’s anorexigenic
efficacy. Opposite to our expectation was the finding that the post-HED hepatic glycogen
content was highly inversely correlated with leptin’s anorexigenic efficacy. Because complete
blockade of leptin signaling causes increased hepatic glycogenolysis leading to lower hepatic
glycogen stores (58), and central leptin administration has the opposite effect (59), the
insensitivity to leptin in the present study apparently does not pertain to all aspects of the
metabolic syndrome. It might be suggested that the reduced central leptin sensitivity of rats in
the present study is compensated by increased leptin actions in peripheral tissues.
A potentially important finding in the present study was that neither the pre-HED anorexigenic
efficacy of MTII nor the post-HED 125I-labeled NDP-MSH binding in the CNS was related to
any parameter linked to DIO. Although the terminal binding study does not necessarily explain
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any factor in the preobese state, the data may suggest that variation in MC receptor signaling
(assessed by food intake suppression as well as by MC receptor binding) does not underlie the
reduced leptin sensitivity of rats in the present study. Thus, although almost 4 months elapsed
between i3cv MTII sensitivity testing and sampling of rat brains for 125I-labeled NDP-MSH
in situ binding study, a period over which animals developed markedly different severities of
DIO, it may be speculated that the differences in the activity of an anorexigenic mechanism
involving MC receptor actions in the PVN is retained irrespective of differences in DIO
development. This may be consistent with the maintained anorexigenic and thermogenic
sensitivity to MTII in DIO rats in other studies (60). There were, however, strong correlations
of MTII’s anorexigenic efficacy with the post-HED 125I-labeled NDP-MSH binding
specifically in the PVN, but not in other regions studied, such as the VMH. The latter region
would be of particular interest because MC receptor binding in the VMH is reduced by
increasing dietary fat content and/or hyperleptinemia (61). MTII’s anorexigenic efficacy and
the post-HED 125I-labeled NDP-MSH binding in the PVN correlated strongly with CRH
immunoreactivity in the PVN. Thus, provided that the differences in PVN CRH
immunoreactivity truly reflect differences in paraventricular CRH peptide content or release
(62), there might be a tight interaction between activity of the MC system and the CRH system
unrelated to the development of DIO.
Taken together, the data in the present study show that i3cv doses of leptin and MTII equated
to produce similar reductions in food intake cause a similar degree of activation (assessed by
cFLI and HPA axis activity) of PVN CRH neurons. Furthermore, reduced sensitivity to leptin
might underlie DIO, but this does not rely on reduced sensitivity to or binding of MC receptor
ligands. Thus, although leptin therapy has been disproved in this and other studies as an
effective treatment strategy to counter DIO (14,19,63), MC receptor agonists may be more
useful (50,64,65,66). The success of the latter strategy may depend on interactions of MC
receptor agonists with PVN CRH neurons.
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Fig. 1.
Effects of i3cv administration of saline (○, n = 5), leptin (•, 3.0 μg, n = 5), and MTII (▾, 0.05
μg, n = 6; ▪, 0.5 μg, n = 6) on plasma levels ACTH, corticosterone (cort), and leptin. Solutions
were given in 3.0-μl volumes at t = 0 min.
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Fig. 2.
Effects of i3cv administration of saline (○, n = 5), leptin (•, 3.0 μg, n = 5), and MTII (▾, 0.05
μg, n = 6; ▪, 0.5 μg, n = 6) on plasma levels glucagon, epinephrine (epi), and norepinephrine
(norepi). Solutions were given in 3.0-μl volumes at t = 0 min.
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Fig. 3.
Representative photomicrographs of the parvocellular and magnocellular region of the PVN.
Neuronal cell bodies were immu-nostained for CRH (indicated as light brown) and c-Fos
(indicated as dark nuclear staining) of rats treated i3cv with saline (A and B), leptin (3.0 μg,
C and D), and MTII (0.05 μg, E and F; 0.5 μg, G and H).
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Fig. 4.
Leptin sensitivity (n = 12) expressed as reduction in 12-h food intake after i3cv leptin
administration relative to saline (%Δ 12h-FI) but not MTII sensitivity (data not shown) before
the HED exposure was significantly correlated to the plasma leptin concentration (A),
abdominal fat mass (B), and liver weight (C) after the HED exposure.
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Fig. 5.
MTII sensitivity (n = 12) expressed as reduction in 12-h food intake after i3cv MTII
administration relative to saline (%Δ 12h-FI) but not leptin sensitivity (data not shown) before
the HED exposure was significantly inversely correlated to CRH labeling (A) and [125I]NDP-
MSH binding (B) in the PVN after the HED exposure.
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TABLE 1
Three-hour and overnight (12-h) food intake in rats after i3cv administration of drugs
Treatment 3 h 12 h
Saline (n = 5) 3.9 ± 0.5 15.5 ± 1.5
Leptin (3.0 μg, n = 5) 1.7 ± 0.6a 9.9 ± 1.0,ad
MTII (0.05 μg, n = 5) 1.4 ± 0.1b 8.4 ± 0.7,bd
MTII (0.5 μg, n = 5) 0.4 ± 0.3c 3.3 ± 0.9c
Values are means ± SEM expressed in grams.
a
P < 0.05;
b
P < 0.01;
c
P < 0.001 relative to saline treatment.
d
P < 0.05 relative to MTII 0.5 μg treatment.
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